NY-AQARA
11.7.2022 09:02:05 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the wide availability of its Curtain Driver E1, a retrofit solution to automate traditional curtains. Build upon the Zigbee 3.0 protocol with improved reliability, range and energy efficiency, the curtain driver features a battery life of up to 12 months between each charge1 , and connects with other smart home accessories to enable truly automated home experiences2 . The Curtain Driver E1 has been made available on Amazon in both North America (US , Canada ) and Europe (UK , France , Germany , Italy , Spain ), as well as via selective Aqara retailers worldwide3 .
With two variants, namely the Rod Version for rods and the Track Version for U-rails and I-rails, the Aqara Curtain Driver E1 are compatible with a majority of curtains on the market. Thanks to its quiet-yet-powerful motor, heavier curtains of up to 12 kilograms can be pulled. It also features a wide compatibility with third-party ecosystems and voice assistants, including HomeKit/Siri, Alexa, Google Home/ Google Assistant, IFTTT, and the upcoming Matter standard will also be supported after its roll-out4 .
The installation is easy. Just mount the Curtain Driver E1 onto the curtain rod or rail, and no additional tools are required. The retrofit solution requires no new wiring to motorize the curtains, and the 6000mAh battery - which lasts for up to 1-year of use - can be charged via the Type-C port. It’s equipped with a built-in light sensor, allowing the curtain to close by its own when it’s too bright, and vice versa.
Apart from ambient brightness, the Curtain Driver can also be smartly controlled by other conditions, such as pre-set schedules, sunrise/sunset, local weather, and geofencing. For example the curtains open at sunset so that the beautiful view won’t be missed. When connect with other Aqara devices, more possibilities are made possible. Use a Wireless Mini Switch to open, close or stop the curtain by a simple press, or adjust the precise opening by turning the Cube. The Camera Hub G3 even allows the curtain to be controlled with hand gestures.
The Curtain Driver is designed with high flexibility to suit for different scenarios and use cases. Device grouping is supported, so that double sided curtains can be controlled simultaneously. The speed of the curtain driver is adjustable, and the device can be configured to work more quietly in the mornings so that the sleep won’t be interrupted anymore. Moreover, it’s possible to set the duration time for curtain movements, for example to pull the curtain from closed to fully open in an hour, which simulates a natural sunrise.
In celebration of the launch, Aqara now offers a 20% discount for the new device on Amazon. North American customers will enjoy the offer with the promo code USCURTAIN in the US and Canada , while European customers will enjoy it using the promo code CURTAINUKEU in France , Germany , Italy , Spain and the UK . Both codes are valid on July 11th , 2022. And Amazon Prime members will continue to enjoy the discount from July 12th to 13th with no promo code required.
For more details of the Curtain Driver E1, please visit our website .
1. Based on the lab test of two devices on the double panel curtains. The actual battery life may vary, depending on curtain weight, track length, and friction.
2. A Zigbee 3.0 Aqara hub is required.
3. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
4. An OTA update of the compatible Aqara hub is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom